

ANTIRETROVIRAL THERAPY FOR HIV INFECTION IN ADULTS AND ADOLESCENTS

Recommendations for a public health approach

2010 revision



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.
– 2010 rev.

1.Anti-retroviral agents - therapeutic use. 2.Anti-retroviral agents - pharmacology. 3.HIV infections – drug therapy.
4.Adult. 5.Adolescent. 6.Guidelines. 7.Developing countries. I.World Health Organization.

ISBN 978 92 4 159976 4

(NLM classification: WC 503.2)

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Austria

ANTIRETROVIRAL THERAPY FOR HIV INFECTION IN ADULTS AND ADOLESCENTS

Recommendations for a public
health approach

2010 revision



CONTENTS

1.	Acronyms and abbreviations.....	1
2.	Acknowledgements.....	5
3.	Executive summary	7
4.	Background.....	8
5.	Funding and declarations of interest.....	9
6.	Guiding principles	10
7.	Objectives of the guidelines and target audience.....	11
8.	Methodology and process	12
9.	From evidence to recommendation	14
10.	Adapting the guidelines	17
11.	Summary of changes	19
12.	Recommendations at a glance	20
13.	When to start.....	24
13.1.	Recommendations	24
13.2.	Evidence.....	24
13.3.	Summary of findings.....	25
13.4.	Benefits and risks	26
13.5.	Acceptability and feasibility.....	26
13.6.	Clinical considerations	27
14.	What to start	31
14.1.	Recommendations	31
14.2.	Evidence.....	31
14.3.	Summary of main findings.....	32
14.4.	Benefits and risks	33
14.5.	Acceptability and feasibility.....	33
14.6.	The choice between NVP and EFV.....	34
14.7.	AZT + 3TC + EFV option	35
14.8.	AZT + 3TC + NVP option.....	36
14.9.	TDF + 3TC (or FTC) + EFV option	37
14.10.	TDF + 3TC (or FTC) + NVP option.....	38
14.11.	Triple NRTI option	39
14.12.	Stavudine (d4T)	39
14.13.	NRTIs not to be used together.....	40

15.	Specific populations – when and what to start	41
15.1.	Recommendations for HIV-infected pregnant women.....	41
15.2.	Recommendations for women with prior exposure to antiretrovirals for PMTCT ..	42
15.3.	Recommendations for HIV/HBV coinfection.....	44
15.4.	Recommendations for HIV/tuberculosis coinfection	45
15.5.	Rifabutin	46
16.	When to switch ART	48
16.1.	Recommendations	48
16.2.	Evidence.....	48
16.3.	Summary of findings.....	48
16.4.	Benefits and risks	49
16.5.	Clinical considerations	50
17.	Second-line regimens	53
17.1.	Recommendations	53
17.2.	Evidence.....	53
17.3.	Summary of findings.....	53
17.4.	Benefits and risks	54
17.5.	Acceptability and feasibility.....	54
17.6.	Clinical considerations	55
17.7.	Selection of second-line NRTIs	56
17.8.	Maintaining 3TC in the second-line regimen	56
17.9.	NRTIs for HIV/HBV coinfection	57
17.10.	Selection of boosted protease inhibitor.....	57
18.	Third-line regimens	58
18.1.	Recommendations.....	58
18.2.	Evidence.....	58
18.3.	Summary of findings.....	58
18.4.	Benefits and risks	59
18.5.	Acceptability and feasibility.....	59
18.6.	Clinical considerations	60
19.	Package of care interventions.....	61
19.1.	Guiding principles	61
19.2.	Voluntary counselling and testing and provider-initiated testing and counselling....	61
19.3.	Preventing further transmission of HIV	61
19.4.	The Three I's for HIV/TB.....	62
19.5.	Cotrimoxazole prophylaxis	62
19.6.	Sexually transmitted infections.....	62
19.7.	Treatment preparedness	63
19.8.	Early initiation of ART.....	63
19.9.	ART as prevention	63

20.	Laboratory monitoring	64
20.1.	Guiding principles	64
20.2.	Laboratory monitoring on ART	65
21.	Annexes.....	67
21.1.	Special note on coinfection with HIV and hepatitis C	67
21.2.	Dosages of recommended antiretrovirals	67
21.3.	Toxicities and recommended drug substitutions.....	69
21.4.	ARV-related adverse events and recommendations	71
21.5.	Diagnostic criteria for HIV-related clinical events	73
21.6.	Grading of selected clinical and laboratory toxicities.....	81
21.7.	Prevention and assessment of HIV drug resistance.....	86
21.8.	Special note on antiretroviral pharmacovigilance.....	87
21.9.	GRADE evidence tables	89
22.	References	126

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>